{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"111-491-960-747-384","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"111-491-960-747-384","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":12063,"type":"PATENT","title":"Wayne State University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2773,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8588,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Wayne State Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2610
Search Applicants and Owners separately:Wayne State Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2610
(a) transforming a set of host cells with a set of plasmids, each plasmid comprising a mutant Pseudomonas aeruginosa 16S rRNA gene and a selectable marker gene;\n\nwherein said mutant Pseudomonas aeruginosa 16S rRNA gene comprises at least one mutation, in addition to a mutant helix 9 sequence and a first mutant Anti-Shine-Dalgarno sequence; and said first selectable marker gene comprises a first mutant Shine-Dalgarno sequence; and\nwherein said first mutant Anti-Shine-Dalgarno sequence and said first mutant Shine-Dalgarno sequence are a mutually compatible pair;\nthereby forming a set of transformed host cells;\n
(b) isolating from the set of transformed host cells those host cells which express the selectable marker gene product; and\n
(c) sequencing the mutant Pseudomonas aeruginosa 16S rRNA gene from each host cell isolated in step (b), thereby identifying functional mutant ribosomes."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the selectable marker gene is a green fluorescent protein gene."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said mutant helix 9 sequence is SEQ ID NO: 1."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the mutant Anti-Shine-Dalgarno sequence is selected from the group consisting of SEQ ID NOs: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146 and 148."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the mutant Shine-Dalgarno sequence is selected from the group consisting of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145 and 147."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the mutant Shine-Dalgarno sequence and the mutant Anti-Shine-Dalgarno sequence are a complementary pair selected from the group consisting of SEQ ID NOs: 7 and 8, 9 and 10, 11 and 12, 13 and 14, 15 and 16, 17 and 18, 19 and 20, 21 and 22, 23 and 24, 25 and 26, 27 and 28, 29 and 30, 31 and 32, 33 and 34, 35 and 36, 37 and 38, 39 and 40, 41 and 42, 43 and 44, 45 and 46, 47 and 48, 49 and 50, 51 and 52, 53 and 54, 55 and 56, 57 and 58, 59 and 60, 61 and 62, 63 and 64, 65 and 66, 67 and 68, 69 and 70, 71 and 72, 73 and 74, 75 and 76, 77 and 78, 79 and 80, 81 and 82, 83 and 84, 85 and 86, 87 and 88, 89 and 90, 91 and 92, 93 and 94, 95 and 96, 97 and 98, 99 and 100, 101 and 102, 103 and 104, 105 and 106, 107 and 108, 109 and 110, 111 and 112, 113 and 114, 115 and 116, 117 and 118, 119 and 120, 121 and 122, 123 and 124, 125 and 126, 127 and 128, 129 and 130, 131 and 132, 133 and 134, 135 and 136, 137 and 138, 139 and 140, 141 and 142, 143 and 144, 145 and 146, and 147 and 148."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the functional mutant ribosomes of step (c) have regions of interest which comprise sequences of one or more nucleic acids which are conserved in each mutant Pseudomonas aeruginosa 16S rRNA gene sequenced; and the method further comprising:\n
(d) generating a second set of mutant Pseudomonas aeruginosa 16S rRNA genes wherein the regions of interest from step (c) are mutated; and each mutant Pseudomonas aeruginosa 16S rRNA gene further comprises a mutant helix 9sequence, and a second mutant Anti-Shine-Dalgarno sequence;\n
(e) inserting the second set of mutant Pseudomonas aeruginosa 16S rRNA genes comprising the mutated regions of interest from step (d) into a second set of plasmids; wherein said plasmids further comprise a second genetically engineered gene which encodes a second selectable marker having a second mutant Shine-Dalgarno sequence, wherein the second mutant Anti-Shine-Dalgarno and the second mutant Shine-Dalgarno sequence are a mutually compatible pair;\n
(f) transforming a second set of host cells with the plasmids from step (e), thereby forming a second set of transformed host cells;\n
(g) isolating from the second set of transformed host cells from step (f) those host cells which express the selectable marker gene product; and\n
(h) sequencing the Pseudomonas aeruginosa 16S rRNA gene from each host cell isolated in step (g), thereby identifying functional mutant ribosomes that may be suitable as drug targets."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the selectable marker gene is a green fluorescent protein gene, and the second selectable marker is a green fluorescent protein."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein said mutant helix 9 sequence is SEQ ID NO: 1."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the mutant Anti-Shine-Dalgarno sequence and the second mutant Anti-Shine-Dalgarno sequence are selected from the group consisting of SEQ ID NOs: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146 and 148."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the mutant Shine-Dalgarno sequence and the second mutant Shine-Dalgarno sequence are each selected from the group consisting of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145 and 147."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the mutant Shine-Dalgarno sequence and the mutant Anti-Shine-Dalgarno sequence and the second mutant Shine-Dalgarno sequence and the second mutant Anti-Shine-Dalgarno sequence are each a complementary pair selected from the group consisting of SEQ ID NOs: 7 and 8, 9 and 10, 11 and 12, 13 and 14, 15 and 16, 17 and 18, 19 and 20, 21 and 22, 23 and 24, 25 and 26, 27 and 28, 29 and 30, 31 and 32, 33 and 34, 35 and 36, 37 and 38, 39 and 40, 41 and 42, 43 and 44, 45 and 46, 47 and 48, 49 and 50, 51 and 52, 53 and 54, 55 and 56, 57 and 58, 59 and 60, 61 and 62, 63 and 64, 65 and 66, 67 and 68, 69 and 70, 71 and 72, 73 and 74, 75 and 76, 77 and 78, 79 and 80, 81 and 82, 83 and 84, 85 and 86, 87 and 88, 89 and 90, 91 and 92, 93 and 94, 95 and 96, 97 and 98, 99 and 100, 101 and 102, 103 and 104, 105 and 106, 107 and 108, 109 and 110, 111 and 112, 113 and 114, 115 and 116, 117 and 118, 119 and 120, 121 and 122, 123 and 124, 125 and 126, 127 and 128, 129 and 130, 131 and 132, 133 and 134, 135 and 136, 137 and 138, 139 and 140, 141 and 142, 143 and 144, 145 and 146, and 147 and 148."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the functional mutant ribosomes of step (c) have regions of interest which comprise sequences of one or more nucleic acids which are conserved in each mutant Pseudomonas aeruginosa 16S rRNA gene sequenced; and the method further comprising:\n
(d) generating a second set of mutant Pseudomonas aeruginosa 16S rRNA genes wherein the regions of interest from step (c) are mutated; and each mutant Pseudomonas aeruginosa 16S rRNA gene further comprises a mutant helix 9sequence, and a second mutant Anti-Shine-Dalgarno sequence;\n
(e) inserting the second set of mutant Pseudomonas aeruginosa 16S rRNA genes comprising the mutated regions of interest from step (d) into a second set of plasmids; wherein said plasmids further comprise a second genetically engineered gene which encodes a second selectable marker having a second mutant Shine-Dalgarno sequence, wherein the second mutant Anti-Shine-Dalgarno and the second mutant Shine-Dalgarno sequence are a mutually compatible pair;\n
(f) transforming a second set of host cells with the plasmids from step (e), thereby forming a second set of transformed host cells;\n
(g) isolating from the second set of transformed host cells from step (f) those host cells which express the selectable marker gene product;\n
(h) sequencing the Pseudomonas aeruginosa 16S rRNA gene from each host cell isolated in step (g), to identify the mutated regions of interest;\n
(i) screening compounds against the mutated regions of interest from step (h) and wildtype Pseudomonas aeruginosa 16S rRNA;\n
(j) identifying the compounds from step (i) that bind to the mutated regions of interest from step (h) and the wildtype Pseudomonas aeruginosa 16S rRNA;\n
(k) screening the compounds from step (j) against human 16S rRNA; and\n
(l) identifying the drug candidates from step (k) that do not bind to the human 16S rRNA, thereby identifying drug candidates."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the selectable marker gene is a green fluorescent protein gene, and the second selectable marker is a green fluorescent protein."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein said mutant helix 9 sequence is SEQ ID NO: 1."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the mutant Anti-Shine-Dalgarno sequence and the second mutant Anti-Shine-Dalgarno sequence are selected from the group consisting of SEQ ID NOs: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146 and 148."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the mutant Shine-Dalgarno sequence and the second mutant Shine-Dalgarno sequence are each selected from the group consisting of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145 and 147."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the mutant Shine-Dalgarno sequence and the mutant Anti-Shine-Dalgarno sequence and the second mutant Shine-Dalgarno sequence and the second mutant Anti-Shine-Dalgarno sequence are each a complementary pair selected from the group consisting of SEQ ID NOs: 7 and 8, 9 and 10, 11 and 12, 13 and 14, 15 and 16, 17 and 18, 19 and 20, 21 and 22, 23 and 24, 25 and 26, 27 and 28, 29 and 30, 31 and 32, 33 and 34, 35 and 36, 37 and 38, 39 and 40, 41 and 42, 43 and 44, 45 and 46, 47 and 48, 49 and 50, 51 and 52, 53 and 54, 55 and 56, 57 and 58, 59 and 60, 61 and 62, 63 and 64, 65 and 66, 67 and 68, 69 and 70, 71 and 72, 73 and 74, 75 and 76, 77 and 78, 79 and 80, 81 and 82, 83 and 84, 85 and 86, 87 and 88, 89 and 90, 91 and 92, 93 and 94, 95 and 96, 97 and 98, 99 and 100, 101 and 102, 103 and 104, 105 and 106, 107 and 108, 109 and 110, 111 and 112, 113 and 114, 115 and 116, 117 and 118, 119 and 120, 121 and 122, 123 and 124, 125 and 126, 127 and 128, 129 and 130, 131 and 132, 133 and 134, 135 and 136, 137 and 138, 139 and 140, 141 and 142, 143 and 144, 145 and 146, and 147 and 148."],"number":18,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}